OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hussain on the Treatment of Nonmetastatic CRPC

July 25th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer

July 25th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

Dr. Nghiem on Immunotherapy in Merkel Cell Carcinoma

July 25th 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses immunotherapy for the treatment of Merkel cell carcinoma.

Dr. Gerber on the Future Landscape of Radiation Oncology

July 25th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

Dr. Razis on the Significance of TERT in the Presence of NF1 in GBM

July 25th 2018

Evangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the significance of TERT mutations in the presence of NF1 mutations in patients with glioblastoma (GBM).

Dr. Weber Discusses Updated Data for CheckMate-238

July 24th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

July 24th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Dr. Kurtz on the Clinical Utility of Cell-Free DNA in Lymphoma

July 24th 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses the utility of cell-free DNA in lymphoma.

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin Lymphoma

July 24th 2018

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses the aim of the ECHELON-1 study in classical Hodgkin lymphoma.

Dr. Matulonis Discusses Rationale of QUADRA Trial

July 24th 2018

Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.

Dr. Stilwill on Optimal Sequencing in Melanoma

July 24th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses optimal sequencing in melanoma.

Dr. Arun on Ongoing Research in Triple-Negative Breast Cancer

July 24th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

July 24th 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

Dr. Lunning Discusses the Treatment of Peripheral T-Cell Lymphoma

July 23rd 2018

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.

Dr. Holstein Discusses Induction Therapy for Multiple Myeloma

July 23rd 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses induction therapy for the treatment of patients with multiple myeloma.

Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors

July 23rd 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.

Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma

July 23rd 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Bekaii-Saab on Adjuvant Therapy in Pancreatic Cancer

July 21st 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.